Oral Ghrelin Receptor Drug MK-0677 Safely Increases IGF-1 by 65% in Hemodialysis Patients

This was a randomized, crossover, double-blind, placebo-controlled study. Twenty-six hemodialysis patients enrolled and 22 completed the 3-month crossover design, receiving both MK-0677 and placebo in alternating periods. The primary outcome was change in serum IGF-1 levels. Statistical analysis used geometric means with 95% confidence intervals, adjusted for pre-intervention IGF-1 concentrations.

Protein-energy wasting affects a large proportion of dialysis patients and is strongly linked to increased morbidity and mortality. Current treatment options are limited — growth hormone injections require subcutaneous administration and produce unnatural GH secretion patterns. MK-0677 offers the advantage of oral dosing while maintaining normal GH secretion physiology, making it a more practical potential treatment. This study establishes safety and IGF-1 efficacy in the target population, a necessary step before larger clinical trials.

This study connects two important fields: ghrelin/growth hormone biology and nephrology supportive care. MK-0677 (ibutamoren) has been studied primarily in aging and growth hormone deficiency, but this is among the first applications in chronic kidney disease. The results support the broader concept that targeting the ghrelin-GH-IGF-1 axis through oral peptide mimetics could improve outcomes in catabolic conditions where muscle wasting drives mortality.

The study had a small sample size (22 completers from 26 enrolled). While IGF-1 increased significantly, the study did not measure clinical outcomes like lean body mass, muscle strength, nutritional status, or survival — only a surrogate biomarker. The 3-month duration may be too short to detect long-term safety concerns or clinical benefits. The study was designed as a preliminary safety/efficacy assessment, not a definitive clinical trial.